HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026. The company will also provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, development of an extended-wear patch, heart attack detection capabilities, and artificial intelligence programs.
The announcement comes as HeartBeam continues to advance its platform technology, which is designed to enable cable-free collection of ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. The company received FDA clearance for its arrhythmia assessment application in December 2024 and for its 12-lead ECG synthesis software in December 2025. These clearances allow physicians to use the HeartBeam System to identify cardiac health trends and acute conditions outside of medical facilities, potentially redefining cardiac health management.
The limited commercial launch for arrhythmia assessment represents a significant step toward bringing the technology to market. The company is also developing an extended-wear patch, which could expand monitoring capabilities for patients over longer periods. Additionally, HeartBeam is investing in AI programs to enhance diagnostic accuracy and clinical decision support. These initiatives are part of the company's broader strategy to deliver actionable heart intelligence through portable devices that can be used wherever the patient is.
HeartBeam holds over 20 issued patents related to its technology enablement, underscoring its commitment to innovation in cardiac care. The company's 3D ECG technology is the first of its kind to receive FDA clearance for both arrhythmia assessment and 12-lead ECG synthesis, positioning it as a potential leader in remote cardiac monitoring.
The first-quarter earnings call will provide investors with insights into the company's financial performance and progress on its strategic milestones. For more details on the cleared indications for use, the company directs stakeholders to its website at https://www.heartbeam.com/indications. The latest news and updates about HeartBeam are available in the company's newsroom at https://nnw.fm/BEAT.
This news matters because HeartBeam's technology has the potential to change how cardiac conditions are detected and monitored, shifting care from hospitals to patients' homes. If successful, the platform could reduce healthcare costs, improve patient outcomes, and expand access to cardiac diagnostics. The upcoming earnings call and strategic updates will be closely watched by investors and industry observers as indicators of the company's trajectory in the competitive medtech landscape.
